報價延遲最少15分鐘:2025/07/18 02:21 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.6 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.71/-0.66
|
|
企業價值
1.32B
|
| 資產負債 |
|
每股賬面淨值
0.58
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
14.00M
|
|
每股收益
0.21
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/18 02:21 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer. |
